GRACE Score Calculator
Estimate in-hospital and 6-month mortality risk in patients presenting with acute coronary syndromes. Guides invasive strategy timing and risk-stratified management decisions across the full ACS spectrum.
Calculate GRACE Score
Enter the eight clinical variables obtained at presentation. All fields are required. This calculator uses the original GRACE risk model point-assignment system validated across STEMI, NSTEMI, and unstable angina. The score provides both in-hospital and 6-month post-discharge mortality estimates.
The GRACE score is a risk estimation tool and does not replace clinical judgement. It applies to the full ACS spectrum (STEMI, NSTEMI, unstable angina) and is intended for use at the time of hospital admission. STEMI patients with ongoing ischaemia require emergent reperfusion regardless of GRACE score. Values should reflect the initial presentation — not post-treatment parameters.
Understanding the GRACE Score
The GRACE (Global Registry of Acute Coronary Events) score was developed from a multinational registry of over 100,000 ACS patients across 247 hospitals in 30 countries. First published by Fox et al. in 2006, it is the most extensively validated risk stratification tool for ACS, endorsed by ESC, AHA/ACC, and NICE guidelines for guiding management decisions in NSTEMI and unstable angina.
The score integrates eight variables that independently predict mortality: age, heart rate, systolic blood pressure, serum creatinine, Killip class, cardiac arrest at admission, ST-segment deviation, and elevated cardiac markers. Each variable is assigned points based on validated ranges, and the total score maps to estimated in-hospital and 6-month post-discharge mortality.
Scoring Components
Age: 0–100 points (continuous, increasing with age)
Heart rate: 0–46 points (higher points for faster rates)
Systolic BP: 0–58 points (higher points for lower BP)
Creatinine: 1–28 points (higher points for elevated values)
Killip class: 0–59 points (Class I to IV)
Cardiac arrest: 0 or 39 points
ST deviation: 0 or 28 points
Elevated markers: 0 or 14 points
GRACE 2.0 — Simplified Version
The GRACE 2.0 model (Fox et al., 2014) uses the same variables but employs a Nomogram-free algorithm that can estimate risk even when one or two variables are missing (by substituting with population averages). It provides a continuous probability estimate rather than a point-based score.
This calculator implements the original point-based GRACE model, which remains the most widely referenced in clinical practice and guidelines. The online GRACE 2.0 calculator is available at www.outcomes-umassmed.org/grace.
Why GRACE over TIMI? While the TIMI risk score is simpler (7 binary variables), GRACE has consistently demonstrated superior discrimination (c-statistic ~0.83 vs. ~0.65 for TIMI) for predicting both in-hospital and 6-month mortality. ESC guidelines specifically recommend GRACE for risk stratification in NSTE-ACS to guide the timing of invasive strategy.
Risk Categories & Mortality Estimates
In-Hospital Mortality
| GRACE Score | Risk Category | In-Hospital Mortality | Management Implication |
|---|---|---|---|
| ≤ 108 | Low | < 1% | Conservative strategy may be appropriate; early non-invasive testing |
| 109–140 | Intermediate | 1–3% | Invasive strategy within 72 hours; individualise based on clinical context |
| > 140 | High | > 3% | Early invasive strategy within 24 hours recommended |
6-Month Post-Discharge Mortality
| GRACE Score | Risk Category | 6-Month Mortality | Post-Discharge Implication |
|---|---|---|---|
| ≤ 88 | Low | < 3% | Standard secondary prevention; outpatient follow-up |
| 89–118 | Intermediate | 3–8% | Intensified secondary prevention; closer follow-up; cardiac rehabilitation |
| > 118 | High | > 8% | Aggressive risk factor modification; early specialist review; consider advanced therapies |
The in-hospital thresholds (≤108 / 109–140 / >140) and 6-month thresholds (≤88 / 89–118 / >118) use different cut-offs from the same score. A patient with a GRACE score of 115 is “intermediate” for in-hospital mortality but “intermediate” for 6-month mortality as well — though the mortality percentages differ. Always report both timeframe interpretations when communicating risk.
GRACE-Guided ACS Management
The GRACE score directly informs the timing of invasive strategy in NSTE-ACS (NSTEMI and unstable angina). ESC 2023 and AHA/ACC 2021 guidelines use GRACE-based risk stratification to determine whether patients should undergo coronary angiography immediately, early, selectively, or conservatively.
Regardless of GRACE score, an immediate invasive strategy (cardiac catheterisation within 2 hours, as for STEMI) is indicated when any of the following are present: haemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical therapy, life-threatening arrhythmias or cardiac arrest, mechanical complications of MI, acute heart failure clearly related to NSTE-ACS, or ST-depression > 1 mm in ≥ 6 leads plus ST-elevation in aVR and/or V1 (suggesting left main or severe multi-vessel disease).
These criteria supersede the GRACE score — the patient requires emergent management regardless of the calculated risk.
Patients with a GRACE score > 140 (high risk) who do not meet criteria for immediate intervention should undergo coronary angiography within 24 hours. This includes patients with dynamic ST/T-wave changes, significant troponin rise and fall consistent with MI, and high GRACE scores driven by combinations of age, haemodynamic compromise, renal dysfunction, and ischaemic ECG changes.
The TIMACS trial demonstrated that an early invasive approach (within 24 hours) reduced the composite of death, MI, and stroke in high-risk NSTE-ACS patients compared with a delayed approach. This benefit was not seen in lower-risk patients.
Intermediate-risk patients (GRACE 109–140) benefit from an invasive strategy within 72 hours. This allows time for medical stabilisation, risk factor assessment, and multidisciplinary discussion. Additional high-risk features that support proceeding with angiography include diabetes, reduced LVEF (< 40%), early post-infarction angina, prior PCI within 6 months, or prior CABG.
During the waiting period, ensure optimal medical therapy: dual antiplatelet therapy (aspirin + P2Y12 inhibitor), anticoagulation (fondaparinux preferred per ESC; enoxaparin or UFH alternatives), beta-blocker, statin, and symptom management with nitrates and analgesia.
Low-risk patients (GRACE ≤ 108) may be managed with an initial conservative approach: optimal medical therapy followed by non-invasive stress testing (exercise ECG, stress echocardiography, or myocardial perfusion imaging) to assess for inducible ischaemia. Angiography is reserved for those with positive non-invasive testing, recurrent symptoms, or new high-risk features.
This does not mean “no further workup” — it means the invasive strategy is deferred in favour of functional testing to guide decision-making. Patients should still receive full anti-ischaemic and secondary prevention therapy. If non-invasive testing reveals significant ischaemia, proceed to angiography.
STEMI always requires emergent reperfusion (primary PCI or fibrinolysis) regardless of GRACE score. The GRACE-guided timing strategy above applies to NSTE-ACS only. Do not delay reperfusion in STEMI to calculate a GRACE score.
Special Populations & Considerations
GRACE in STEMI: While GRACE was validated across all ACS types, its primary clinical utility is in NSTE-ACS where it guides invasive timing. In STEMI, the management pathway is determined by the ST-elevation itself (emergent reperfusion), not by a calculated risk score. GRACE remains useful in STEMI for prognostication and post-discharge risk assessment, but should never delay reperfusion.
Stepwise ACS Assessment Workflow
Obtain a 12-lead ECG within 10 minutes of first medical contact. Classify as STEMI (persistent ST-elevation or new LBBB → emergent reperfusion pathway, GRACE not needed for timing), NSTEMI (troponin rise + ischaemic symptoms/ECG changes), or unstable angina (ischaemic symptoms without troponin rise). For NSTEMI and UA, proceed to step 2.
While calculating the GRACE score, initiate: aspirin 300 mg loading dose, anticoagulation (fondaparinux 2.5 mg SC, or enoxaparin, or UFH), nitrates for ongoing pain (sublingual then IV if needed), morphine for refractory pain, oxygen only if SpO₂ < 90%, and beta-blocker (if no contraindications). P2Y12 inhibitor loading (ticagrelor 180 mg or clopidogrel 600 mg) — timing depends on whether immediate angiography is planned (may defer P2Y12 until coronary anatomy is known).
Calculate GRACE using admission variables. Cross-reference with the four-tier management strategy: immediate (< 2h) for very-high-risk criteria regardless of score; early (< 24h) for GRACE > 140; selective (< 72h) for GRACE 109–140; conservative for GRACE ≤ 108 with non-invasive testing first. Document the score, the risk category, and the planned strategy in the medical record.
High ischaemic risk often coexists with high bleeding risk (elderly, CKD, low body weight). Use a bleeding risk tool (CRUSADE, ARC-HBR criteria) to guide antithrombotic intensity. Key decisions include: choice of P2Y12 inhibitor (ticagrelor/prasugrel vs. clopidogrel), use of GP IIb/IIIa inhibitors, access site for PCI (radial preferred for bleeding reduction), and proton pump inhibitor co-prescription.
Recalculate GRACE at discharge for 6-month mortality estimation. High 6-month risk (> 118) warrants intensified secondary prevention: high-intensity statin, DAPT optimisation, aggressive BP and glucose control, cardiac rehabilitation referral, early specialist follow-up, and consideration of advanced therapies (LVAD, transplant evaluation if severely reduced EF). Reassess LVEF at 6–12 weeks; consider ICD for primary prevention if EF ≤ 35% despite optimal medical therapy for ≥ 3 months.
Common Pitfalls & Limitations
The GRACE score guides invasive timing in NSTE-ACS only. STEMI patients with persistent ST-elevation require emergent reperfusion (primary PCI door-to-balloon < 90 minutes, or fibrinolysis door-to-needle < 30 minutes) regardless of any calculated risk score. Stopping to calculate a GRACE score in the setting of STEMI is inappropriate and delays life-saving treatment. The score can be calculated retrospectively for prognostication and discharge planning.
With high-sensitivity troponin assays, troponin elevations are common in non-ACS conditions: sepsis, pulmonary embolism, myocarditis, takotsubo cardiomyopathy, heart failure exacerbation, renal failure, and procedural myocardial injury. The GRACE score was derived and validated only in patients with confirmed ACS. Applying it to a patient with sepsis-related troponin elevation will generate a misleadingly high score that could trigger an inappropriate invasive strategy. Always confirm the clinical diagnosis of ACS before using GRACE.
A young patient with a low GRACE score can still have very-high-risk features that mandate immediate invasive management — such as dynamic ECG changes with ongoing pain, ventricular arrhythmias, or haemodynamic instability. The “very high risk” criteria (ESC) supersede the GRACE-based timing pathway. A low score does not guarantee a benign course; it estimates population-level mortality risk, not individual prognosis. Clinical judgement must always be integrated with the score.
GRACE should be calculated using values obtained at initial presentation — before any therapeutic intervention. Heart rate and blood pressure measured after beta-blocker administration, inotrope support, or fluid resuscitation do not reflect the patient’s baseline risk. Using improved post-treatment haemodynamics will underestimate the true GRACE score and may lead to inappropriately deferred invasive management. Document the time of measurement alongside the score.
The risk categories use different score thresholds for in-hospital mortality (≤108 / 109–140 / >140) and 6-month post-discharge mortality (≤88 / 89–118 / >118). Confusing these thresholds is common and can lead to miscommunication. A patient with GRACE = 100 is “low” in-hospital risk but actually “intermediate” for 6-month mortality. Always specify which timeframe you are referencing when discussing GRACE risk categories with colleagues or in documentation.
Quick Reference Summary
in the GRACE model
strategy < 24 hours
mortality prediction
GRACE registry
| GRACE Score | In-Hospital Mortality | 6-Month Mortality | NSTE-ACS Invasive Timing |
|---|---|---|---|
| ≤ 108 (in-hosp) / ≤ 88 (6-mo) | < 1% | < 3% | Conservative → non-invasive testing first |
| 109–140 / 89–118 | 1–3% | 3–8% | Selective invasive within 72 hours |
| > 140 / > 118 | > 3% | > 8% | Early invasive within 24 hours |
| Any score + very-high-risk criteria | Variable — critical | Immediate invasive < 2 hours (as for STEMI) | |
The Golden Rule: GRACE guides timing, not the decision to treat. Every ACS patient receives medical therapy. The score determines when to proceed with angiography in NSTE-ACS, not whether to treat. STEMI always requires emergent reperfusion regardless of the score. And clinical judgement always supersedes any calculated number.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. DOI: 10.1136/bmj.38985.646481.55
- Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Archives of Internal Medicine. 2003;163(19):2345-2353. DOI: 10.1001/archinte.163.19.2345
- Fox KAA, FitzGerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open. 2014;4(2):e004425. DOI: 10.1136/bmjopen-2013-004425
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289-1367. DOI: 10.1093/eurheartj/ehaa575
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826. DOI: 10.1093/eurheartj/ehad191
- Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;130(25):e344-e426. DOI: 10.1161/CIR.0000000000000134
- Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes (TIMACS). New England Journal of Medicine. 2009;360(21):2165-2175. DOI: 10.1056/NEJMoa0807986
- Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock (SHOCK). New England Journal of Medicine. 1999;341(9):625-634. DOI: 10.1056/NEJM199908263410901
- Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727-2733. DOI: 10.1001/jama.291.22.2727
- Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842. DOI: 10.1001/jama.284.7.835